Larson Financial Group LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 4.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,010 shares of the biopharmaceutical company’s stock after selling 564 shares during the quarter. Larson Financial Group LLC’s holdings in Pfizer were worth $470,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Usca Ria LLC lifted its holdings in shares of Pfizer by 11.6% in the second quarter. Usca Ria LLC now owns 504,526 shares of the biopharmaceutical company’s stock valued at $19,757,000 after purchasing an additional 52,362 shares in the last quarter. Cito Capital Group LLC raised its position in Pfizer by 59.6% in the 1st quarter. Cito Capital Group LLC now owns 38,831 shares of the biopharmaceutical company’s stock valued at $1,407,000 after buying an additional 14,500 shares during the last quarter. Advisor Group Holdings Inc. boosted its position in Pfizer by 4.4% during the 2nd quarter. Advisor Group Holdings Inc. now owns 2,090,666 shares of the biopharmaceutical company’s stock worth $81,925,000 after acquiring an additional 88,276 shares during the last quarter. Guggenheim Capital LLC grew its stake in shares of Pfizer by 2.8% during the 1st quarter. Guggenheim Capital LLC now owns 1,461,508 shares of the biopharmaceutical company’s stock worth $52,950,000 after acquiring an additional 40,497 shares in the last quarter. Finally, Carolina Wealth Advisors LLC raised its holdings in shares of Pfizer by 7.1% in the second quarter. Carolina Wealth Advisors LLC now owns 112,745 shares of the biopharmaceutical company’s stock valued at $4,415,000 after purchasing an additional 7,456 shares during the last quarter. 64.93% of the stock is currently owned by institutional investors.
In other Pfizer news, SVP Jennifer B. Damico sold 1,661 shares of the business’s stock in a transaction that occurred on Friday, August 13th. The shares were sold at an average price of $48.30, for a total transaction of $80,226.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jennifer B. Damico sold 2,500 shares of the business’s stock in a transaction on Friday, July 30th. The stock was sold at an average price of $42.86, for a total value of $107,150.00. Following the transaction, the senior vice president now directly owns 11,430 shares of the company’s stock, valued at approximately $489,889.80. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.10. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. The firm had revenue of $18.98 billion during the quarter, compared to the consensus estimate of $17.54 billion. During the same quarter in the previous year, the firm posted $0.78 EPS. Equities analysts predict that Pfizer Inc. will post 4.12 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 7th. Shareholders of record on Friday, July 30th were issued a $0.39 dividend. The ex-dividend date was Thursday, July 29th. This represents a $1.56 annualized dividend and a yield of 3.47%. Pfizer’s dividend payout ratio is presently 70.27%.
A number of research analysts recently weighed in on PFE shares. SVB Leerink reaffirmed a “hold” rating and issued a $49.00 target price on shares of Pfizer in a research report on Tuesday. Mizuho lifted their target price on Pfizer from $42.00 to $43.00 and gave the company a “neutral” rating in a research report on Friday, July 30th. Berenberg Bank reissued a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Tuesday, June 15th. Truist started coverage on Pfizer in a report on Tuesday, July 27th. They issued a “buy” rating and a $43.00 price objective for the company. Finally, Royal Bank of Canada set a $44.00 price target on shares of Pfizer in a research report on Thursday, July 29th. Eleven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $42.77.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.